Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 5
2007 6
2008 2
2009 4
2010 5
2011 8
2012 3
2013 5
2014 7
2015 4
2016 7
2017 11
2018 7
2019 8
2020 13
2021 21
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean brain head (95,312 results)?
Amyloid precursor protein induces reactive astrogliosis.
Velezmoro Jauregui G, Vukić D, Onyango IG, Arias C, Novotný JS, Texlová K, Wang S, Kovačovicova KL, Polakova N, Zelinkova J, Čarna M, Lacovich V, Head BP, Havas D, Mistrik M, Zorec R, Verkhratsky A, Keegan L, O'Connell MA, Rissman R, Stokin GB. Velezmoro Jauregui G, et al. Among authors: head bp. Acta Physiol (Oxf). 2024 Apr 8:e14142. doi: 10.1111/apha.14142. Online ahead of print. Acta Physiol (Oxf). 2024. PMID: 38584589
Amyloid precursor protein induces reactive astrogliosis.
Jauregui GV, Vukić D, Onyango IG, Arias C, Novotný JS, Texlová K, Wang S, Kovačovicova KL, Polakova N, Zelinkova J, Čarna M, Strašil VL, Head BP, Havas D, Mistrik M, Zorec R, Verkhratsky A, Keegan L, O'Connel M, Rissman R, Stokin GB. Jauregui GV, et al. Among authors: head bp. bioRxiv [Preprint]. 2023 Dec 18:2023.12.18.571817. doi: 10.1101/2023.12.18.571817. bioRxiv. 2023. PMID: 38187544 Free PMC article. Updated. Preprint.
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
Portal-Celhay C, Forleo-Neto E, Eagan W, Musser BJ, Davis JD, Turner KC, Norton T, Hooper AT, Hamilton JD, Pan C, Mahmood A, Baum A, Kyratsous CA, Kim Y, Parrino J, Kampman W, Roque-Guerrero L, Stoici R, Fatakia A, Soo Y, Geba GP, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman GA, Yancopoulos GD, Weinreich DM; COVID-19 Phase 2 Dose-Ranging Study Team. Portal-Celhay C, et al. JAMA Netw Open. 2022 Aug 1;5(8):e2225411. doi: 10.1001/jamanetworkopen.2022.25411. JAMA Netw Open. 2022. PMID: 35969402 Free PMC article. Clinical Trial.
Subpial delivery of adeno-associated virus 9-synapsin-caveolin-1 (AAV9-SynCav1) preserves motor neuron and neuromuscular junction morphology, motor function, delays disease onset, and extends survival in hSOD1G93A mice.
Wang S, Ichinomiya T, Savchenko P, Wang D, Sawada A, Li X, Duong T, Li W, Bonds JA, Kim EJ, Miyanohara A, Roth DM, Patel HH, Patel PM, Tadokoro T, Marsala M, Head BP. Wang S, et al. Among authors: head bp. Theranostics. 2022 Jul 11;12(12):5389-5403. doi: 10.7150/thno.72614. eCollection 2022. Theranostics. 2022. PMID: 35910808 Free PMC article.
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Herman GA, O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Musser BJ, Davis JD, Turner KC, Mahmood A, Hooper AT, Hamilton JD, Parrino J, Subramaniam D, Baum A, Kyratsous CA, DiCioccio AT, Stahl N, Braunstein N, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. Herman GA, et al. Lancet Infect Dis. 2022 Oct;22(10):1444-1454. doi: 10.1016/S1473-3099(22)00416-9. Epub 2022 Jul 5. Lancet Infect Dis. 2022. PMID: 35803290 Free PMC article. Clinical Trial.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. O'Brien MP, et al. JAMA. 2022 Feb 1;327(5):432-441. doi: 10.1001/jama.2021.24939. JAMA. 2022. PMID: 35029629 Free PMC article. Clinical Trial.
Rising to Ostrom's challenge: an invitation to walk on the bright side of public governance and public service.
Douglas S, Schillemans T, 't Hart P, Ansell C, Bøgh Andersen L, Flinders M, Head B, Moynihan D, Nabatchi T, O'Flynn J, Peters BG, Raadschelders J, Sancino A, Sørensen E, Torfing J. Douglas S, et al. Among authors: head b. Policy Des Pract. 2021 Sep 3;4(4):441-451. doi: 10.1080/25741292.2021.1972517. eCollection 2021. Policy Des Pract. 2021. PMID: 34805773 Free PMC article.
Vitamin E: How much is enough, too much and why!
Traber MG, Head B. Traber MG, et al. Among authors: head b. Free Radic Biol Med. 2021 Dec;177:212-225. doi: 10.1016/j.freeradbiomed.2021.10.028. Epub 2021 Oct 23. Free Radic Biol Med. 2021. PMID: 34699937 Review.
110 results